BioArctic AB Class B BIOA B

STO: BIOA B | ISIN: SE0010323311 13/06/2025

198,40 SEK (-1,59%)

(-1,59%) 13/06/2025

Grafiek BioArctic AB Class B

Grafiek BioArctic AB Class B

1 dag1d -1,59%
1 week1w -1,68%
1 maand1m 7,83%
3 maanden3m -4,62%
6 maanden6m 16,71%
1 jaar1j -8,66%
5 jaar5j 171,22%

BioArctic AB Class B in het nieuws

Toon enkel gratis nieuws

15 mei 2025 · Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 - March 2026) · Persbericht

13 mei 2025 · Invitation to presentation of BioArctic's first quarter report for January - March 2025 on May 21 at 9.30 a.m. CET · Persbericht

8 mei 2025 · Exidavnemab phase 2a study expanded to include MSA patients · Persbericht

1 april 2025 · The European Commission refers lecanemab decision to Appeal Committee · Persbericht

25 maart 2025 · BioArctic's partner Eisai presents sales simulation for Leqembi® at its annual press conference · Persbericht

17 maart 2025 · BioArctic receives Orphan Drug Designation for exidavnemab the US · Persbericht

12 maart 2025 · Lars Lannfelt, Pär Gellerfors, and Gunilla Osswald awarded Uppsala University's Innovation and Entrepreneurship Prize · Persbericht

3 maart 2025 · Therapeutic Goods Administration decides not to register lecanemab in Australia · Persbericht

27 augustus 2024 · Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology · Persbericht

22 augustus 2024 · Leqembi (lecanemab) authorized for early Alzheimer's disease in Great Britain · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe